These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1747 related articles for article (PubMed ID: 30703795)

  • 21. Is neoadjuvant chemoradiation with dose-escalation and consolidation chemotherapy sufficient to increase surgery-free and distant metastases-free survival in baseline cT3 rectal cancer?
    São Julião GP; Habr-Gama A; Vailati BB; Aguilar PB; Sabbaga J; Araújo SEA; Mattacheo A; Alexandre FA; Fernandez LM; Gomes DB; Gama-Rodrigues J; Perez RO
    Eur J Surg Oncol; 2018 Jan; 44(1):93-99. PubMed ID: 29217398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis on risk factors of the degree of radical resection and prognosis of patients with locally recurrent rectal cancer].
    Zhang JL; Wu T; Chen GW; Wang PY; Jiang Y; Tang JQ; Wu YC; Pan YS; Liu YC; Wan YL; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 May; 23(5):472-479. PubMed ID: 32842427
    [No Abstract]   [Full Text] [Related]  

  • 23. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
    Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
    Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
    Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
    Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid/low rectal cancer with clinically suspected lateral node involvement: a multicenter retrospective cohort study.
    Oh HK; Kang SB; Lee SM; Lee SY; Ihn MH; Kim DW; Park JH; Kim YH; Lee KH; Kim JS; Kim JW; Kim JH; Chang TY; Park SC; Sohn DK; Oh JH; Park JW; Ryoo SB; Jeong SY; Park KJ
    Ann Surg Oncol; 2014 Jul; 21(7):2280-7. PubMed ID: 24604580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term results and long-term oncologic outcomes between neoadjuvant chemoradiotherapy and adjuvant postoperative chemoradiotherapy for stage III rectal cancer: a case-matched study.
    Kang J; Jang SM; Baek JH; Lee WS; Cho TH
    Ann Surg Oncol; 2012 Aug; 19(8):2494-9. PubMed ID: 22476817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ≥ 70 Years With Locally Advanced Rectal Cancer.
    Jacobs L; van der Vlies E; Ten Bokkel Huinink D; Bloemendal H; Intven M; Smits AB; Weusten BLAM; Siersema PD; van Lelyveld N; Los M
    Clin Colorectal Cancer; 2018 Sep; 17(3):179-186. PubMed ID: 29661620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of neoadjuvant chemoradiotherapy combined with lateral lymph nodes dissection or not on the local recurrence of low to intermediate-stage II/III rectal cancer.
    Li C; Luan J; Ji X; Wang X; Li J; Li X; Zhou Y
    J Surg Oncol; 2024 Feb; 129(2):273-283. PubMed ID: 37811551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
    Velenik V; Oblak I; Anderluh F
    Radiat Oncol; 2010 Sep; 5():88. PubMed ID: 20920276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant Chemotherapy Is Associated With Improved Overall Survival in Locally Advanced Rectal Cancer After Achievement of a Pathologic Complete Response to Chemoradiation.
    Shahab D; Gabriel E; Attwood K; Ma WW; Francescutti V; Nurkin S; Boland PM
    Clin Colorectal Cancer; 2017 Dec; 16(4):300-307. PubMed ID: 28420585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.
    Sun Y; Wu X; Zhang Y; Lin H; Lu X; Huang Y; Chi P
    Eur J Surg Oncol; 2019 Jul; 45(7):1225-1231. PubMed ID: 30879932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer.
    Yang Y; Liu Q; Jia B; Du X; Dai G; Liu H; Chen J; Zeng M; Wen K; Zhu Y; Wang Y; Feng L
    Technol Cancer Res Treat; 2019 Jan; 18():1533033818824367. PubMed ID: 30803368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
    Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Retrospective study of role of neoadjuvant rectal scores in evaluating the 10-year disease-free survival of patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy followed by surgery].
    Zhang WL; Zhou C; Wang WF; Li WH; He JH; Lu ZH; Wu XJ; Lin JZ; Peng JH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jun; 27(6):608-614. PubMed ID: 38901994
    [No Abstract]   [Full Text] [Related]  

  • 37. [Construction of a model based on multipoint full-layer puncture biopsy for predicting pathological complete response after neoadjuvant therapy for locally advanced rectal cancer].
    Jin Y; Zhai ZW; Sun LT; Xia PD; Hu H; Jiang CQ; Zhao BC; Qu H; Qian Q; Dai Y; Yao HW; Wang ZJ; Han JG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):403-411. PubMed ID: 38644246
    [No Abstract]   [Full Text] [Related]  

  • 38. Persistent involvement of anterior mesorectal fascia in carcinoma rectum - extended resection of rectum vs total pelvic exenteration: results from a single-centre retrospective study.
    Verma K; Engineer R; Ostwal V; Kumar S; Arya S; Desouza AL; Saklani AP
    Colorectal Dis; 2018 Dec; 20(12):1070-1077. PubMed ID: 29985547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of exenteration in cT4 and fixed cT3 stage primary rectal adenocarcinoma: a subgroup analysis of consolidation chemotherapy following neoadjuvant concurrent chemoradiotherapy.
    Kumar NA; Desouza A; Ostwal V; Sasi SP; Verma K; Ramaswamy A; Engineer R; Saklani A
    Langenbecks Arch Surg; 2021 May; 406(3):821-831. PubMed ID: 33733285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal treatment strategy for rectal cancer based on the risk factors for recurrence patterns.
    Yamamoto T; Kawada K; Hida K; Ganeko R; Inamoto S; Yoshitomi M; Watanabe T; Sakai Y
    Int J Clin Oncol; 2019 Jun; 24(6):677-685. PubMed ID: 30721379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 88.